Patent intelligence · US
US 10376582
Buffer formulations for enhanced antibody stability
Buffer formulations for enhanced antibody stability
Patent details — US 10376582
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 13, 2019
- Expiration
- Aug 8, 2039
- Applicant
- Outlook Therapeutics, Inc.
- Claims
- 82
- CPC classes
- A61K, A61K39/39591, A61K47/02, A61K47/12
Quick answer
US 10376582 (Buffer formulations for enhanced antibody stability) is held by Outlook Therapeutics, Inc.. Status: granted. Granted Aug 13, 2019. Expires Aug 8, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Outlook Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 82
- CPC classes
- A61K, A61K39/39591, A61K47/02, A61K47/12, A61K47/26, A61K9/08
More from Outlook Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 10376582?
US 10376582 (Buffer formulations for enhanced antibody stability) is held by Outlook Therapeutics, Inc.. Status: granted. Granted Aug 13, 2019. Expires Aug 8, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10376582?
Outlook Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 10376582 expire?
Our index shows an expiration date of Aug 8, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.